Entera Bio Ltd.
ENTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001638097
No open-market purchases or sales by Entera Bio Ltd. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $19.0M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Entera Bio Ltd. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 26 | 27 | +1 |
| Shares | 7.87M | 10.7M | +2.86M (+36.3%) |
| Value | $8.68M | $19.0M | +$10.3M (+118.8%) |
New holders (7)
Institutions that held Entera Bio Ltd. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BVF Inc | 2,425,000 | $4.29M | 0.11% |
| Siren, L.L.C. | 736,457 | $1.30M | 0.03% |
| Two Sigma Securities, LLC | 48,593 | $86.0K | 0.01% |
| Virtu Financial LLC | 36,921 | $65.0K | 0.00% |
| Simplex Trading, LLC | 15,698 | $27.8K | 0.00% |
| SG Americas Securities, LLC | 13,913 | $25.0K | 0.00% |
| BNP Paribas Arbitrage, SA | 400 | $708 | 0.00% |
Sold out (6)
Institutions that held Entera Bio Ltd. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Marshall Wace, LLP | 195,780 | $217.3K |
| Northern Trust Corp | 146,854 | $163.0K |
| Point72 Asset Management, L.P. | 12,382 | $13.7K |
| Bank of America Corp | 12,000 | $13.3K |
| Caitong International Asset Management Co., Ltd | 20 | $22 |
| SBI Securities Co., Ltd. | 2 | $2 |